Carreras Joaquim, Villamor Neus, Colomo Lluís, Moreno Carol, Ramón y Cajal Santiago, Crespo Marta, Tort Frederic, Bosch Francesc, López-Guillermo Armando, Colomer Dolors, Montserrat Emili, Campo Elías
Haemopathology Unit, Department of Pathology, Hospital Clinic, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain.
J Pathol. 2005 Mar;205(4):507-13. doi: 10.1002/path.1727.
ZAP-70 is a tyrosine kinase that participates in early B-cell differentiation and is a prognostic factor in chronic lymphocytic leukaemia (CLL), where it is associated with an unmutated configuration of the IgV(H) genes. In this study ZAP-70 expression was studied by immunohistochemistry in a spectrum of B-cell lymphoid neoplasms; this staining method was compared with flow cytometry, and the relationship of ZAP-70 expression to mutational status and prognosis was assessed. 242 tissue samples from 225 patients with B-cell lymphoid neoplasms arising at different maturational stages were included. Flow cytometry was performed in all CLL cases (n = 52). IgV(H) mutational status was determined in 25 CLL and 12 mantle cell lymphoma (MCL) patients. ZAP-70 was positive in 34/52 (65%) CLL, 9/31 (31%) Burkitt's lymphoma, 2/7 (29%) lymphoblastic lymphomas, 3/36 (8%) MCL, 1/23 (4%) marginal zone lymphoma, and 1/45 (2%) diffuse large B-cell lymphomas, but in none of the 19 follicular lymphomas or the 14 Hodgkin lymphomas. An identical ZAP-70 pattern was obtained in six patients with simultaneous biopsies from different sites and in 12 patients with sequential biopsies. Immunohistochemistry and flow cytometry gave identical results in 48 the 52 CLLs. All but one ZAP-70-positive CLL had IgV(H) gene in an unmutated configuration, whereas all but one ZAP-70-negative CLL had somatically hypermutated IgV(H). The 12 MCLs analysed were ZAP-70 negative regardless of IgV(H) mutational status (4 mutated, 8 unmutated). ZAP-70 positive CLL was associated with a shorter overall survival (median time 103 months vs. 293 months, p = 0.01) and a shorter time to disease progression (median time 26 months vs. 60 months, p = 0.01). In conclusion, ZAP-70 is expressed in several types of B-cell neoplasm and is easily detected by immunohistochemistry, providing a useful prognostic marker in patients with CLL from whom no other material is available or when other techniques for its assessment cannot be performed.
ZAP-70是一种酪氨酸激酶,参与早期B细胞分化,是慢性淋巴细胞白血病(CLL)的一个预后因素,在CLL中它与IgV(H)基因的未突变构型相关。在本研究中,通过免疫组织化学方法研究了一系列B细胞淋巴瘤中ZAP-70的表达;将这种染色方法与流式细胞术进行了比较,并评估了ZAP-70表达与突变状态及预后的关系。纳入了来自225例处于不同成熟阶段的B细胞淋巴瘤患者的242份组织样本。对所有CLL病例(n = 52)进行了流式细胞术检测。测定了其中25例CLL患者和12例套细胞淋巴瘤(MCL)患者的IgV(H)突变状态。ZAP-70在34/52(65%)的CLL、9/31(31%)的伯基特淋巴瘤、2/7(29%)的淋巴细胞淋巴瘤、3/36(8%)的MCL、1/23(4%)的边缘区淋巴瘤和1/45(2%)的弥漫性大B细胞淋巴瘤中呈阳性,但在19例滤泡性淋巴瘤或14例霍奇金淋巴瘤中均未呈阳性。在6例同时进行不同部位活检的患者以及12例进行序贯活检的患者中获得了相同的ZAP-70表达模式。在52例CLL患者中,免疫组织化学和流式细胞术结果在48例中一致。除1例ZAP-70阳性CLL外,其余所有患者的IgV(H)基因均为未突变构型,而除1例ZAP-70阴性CLL外,其余所有患者的IgV(H)均发生了体细胞超突变。所分析的12例MCL无论IgV(H)突变状态如何(4例突变,8例未突变)均为ZAP-70阴性。ZAP-70阳性的CLL患者总生存期较短(中位时间103个月对29